Abivax S.A.(ABVX)

POST5.320.000.00%16:00 EDT

5.32-0.47-8.12%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Abivax publishes financial reports with the French and U.S. securities regulatory agencies
  GlobeNewswire · 03-26
  Abivax publishes financial reports with the French and U.S. securities regulatory agencies
- Abivax FY24 Net loss Stood At €(176.2)M Vs. €(147.8)M In FY23
  Benzinga · 03-24
  Abivax FY24 Net loss Stood At €(176.2)M Vs. €(147.8)M In FY23
- Abivax Cash Position Stood At €144M As Of December 31, 2024
  Benzinga · 03-24
  Abivax Cash Position Stood At €144M As Of December 31, 2024
- Abivax SA expected to post a loss of 68 cents a share - Earnings Preview
  Reuters · 03-21
  Abivax SA expected to post a loss of 68 cents a share - Earnings Preview
- Abivax SA Sponsored ADR (ABVX) Gets a Buy from Piper Sandler
  TIPRANKS · 03-10
  Abivax SA Sponsored ADR (ABVX) Gets a Buy from Piper Sandler
- Piper Sandler Sticks to Their Buy Rating for Abivax SA Sponsored ADR (ABVX)
  TIPRANKS · 02-10
  Piper Sandler Sticks to Their Buy Rating for Abivax SA Sponsored ADR (ABVX)
- Morgan Stanley Sticks to Its Hold Rating for Abivax SA Sponsored ADR (ABVX)
  TIPRANKS · 01-28
  Morgan Stanley Sticks to Its Hold Rating for Abivax SA Sponsored ADR (ABVX)
- Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
  GlobeNewswire · 01-23
  Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
- Analysts Offer Insights on Healthcare Companies: IGM Biosciences (IGMS) and Abivax SA Sponsored ADR (ABVX)
  TIPRANKS · 01-10
  Analysts Offer Insights on Healthcare Companies: IGM Biosciences (IGMS) and Abivax SA Sponsored ADR (ABVX)
- Abivax Reaches 82% Enrollment in Phase 3 Ulcerative Colitis Trial
  MT Newswires Live · 01-09
  Abivax Reaches 82% Enrollment in Phase 3 Ulcerative Colitis Trial
- Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
  GlobeNewswire · 01-09
  Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
- Abivax Announces A Change To The Composition Of Its Board Of Directors
  T-Reuters · 2024-12-23
  Abivax Announces A Change To The Composition Of Its Board Of Directors
- Abivax SA Sponsored ADR (ABVX) Gets a Buy from JMP Securities
  TIPRANKS · 2024-12-05
  Abivax SA Sponsored ADR (ABVX) Gets a Buy from JMP Securities
- Stock Track | Abivax Soars 5.54% as Analyst Initiates Coverage with Bullish Outlook
  Stock Track · 2024-12-04
  Stock Track | Abivax Soars 5.54% as Analyst Initiates Coverage with Bullish Outlook
- JMP Securities Initiates Abivax at Market Outperform With $33 Price Target
  MT Newswires Live · 2024-12-04
  JMP Securities Initiates Abivax at Market Outperform With $33 Price Target
- Abivax Initiates $150 Million ATM Program on Nasdaq
  TIPRANKS · 2024-11-19
  Abivax Initiates $150 Million ATM Program on Nasdaq
- Abivax Q3 Total Principal Debt Outstanding €106.3M Down From €108.4M YoY
  Benzinga · 2024-11-14
  Abivax Q3 Total Principal Debt Outstanding €106.3M Down From €108.4M YoY
- Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Abivax SA Sponsored ADR (ABVX) and Aquestive Therapeutics (AQST)
  TIPRANKS · 2024-10-08
  Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Abivax SA Sponsored ADR (ABVX) and Aquestive Therapeutics (AQST)
Company Profile
Company Name
Abivax S.A.
Market
NASDAQ
Establishment Date
2013
Employees
69
Office Location
7-11 boulevard Haussmann,Paris,Ile-de-France,France
Website
http://www.abivax.com
Zip Code
75009
Phone
33 1 53 83 09 63
Fax
- -
Introduction
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Industry
Biotechnology
IPO Information
Listing Date
2023-10-20
Issue Price
11.6
- 03-24
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 03-24
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2024-11-25
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-11-14
  Beneficial Ownership Change
  Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 2024-04-19
  Beneficial Ownership Change
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
- 2024-04-05
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2024-02-14
  Beneficial Ownership Change
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
- 2023-11-22
  Beneficial Ownership Change
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
- 2023-10-30
  Beneficial Ownership Change
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
- 2023-10-30
  Beneficial Ownership Change
  Form SC 13D - General statement of acquisition of beneficial ownership
  Form SC 13D - General statement of acquisition of beneficial ownership
- 2023-10-20
  [Supp]Public Prospectus
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
- 2023-10-18
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2023-10-18
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2023-10-18
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2023-10-18
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]

1D
5D
Day
Week
Month

High

5.75

Open

5.54

Volume%

0.84

Low

5.16

5.79

T/O Rate

0.50%

抱歉，当前请求异常(-1)

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

Abivax S.A.(ABVX)

Company Profile

Industry

IPO Information